Herboxidiene Features That Mediate Conformation-Dependent SF3B1 Interactions to Inhibit Splicing

被引:9
|
作者
Lopez, Adriana Gamboa [1 ,2 ]
Allu, Srinivasa Rao [3 ,4 ]
Mendez, Patricia [1 ,2 ]
Reddy, Guddeti Chandrashekar [3 ,4 ]
Maul-Newby, Hannah M. [1 ,2 ]
Ghosh, Arun K. [3 ,4 ]
Jurica, Melissa S. [1 ,2 ]
机构
[1] Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA
[2] Univ Calif Santa Cruz, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA
[3] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[4] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
D O I
10.1021/acschembio.0c00965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Small molecules that target the spliceosome SF3B complex are potent inhibitors of cancer cell growth. The compounds affect an early stage of spliceosome assembly when U2 snRNP first engages the branch point sequence of an intron. Employing an inactive herboxidiene analog (iHB) as a competitor, we investigated factors that influence inhibitor interactions with SF3B to interfere with pre-mRNA splicing in vitro. Order-of-addition experiments show that inhibitor interactions are long lasting and affected by both temperature and the presence of ATP. Our data are also consistent with the model that not all SF3B conformations observed in structural studies are conducive to productive inhibitor interactions. Notably, SF3B inhibitors do not impact an ATP-dependent rearrangement in U2 snRNP that exposes the branch binding sequence for base pairing. We also report extended structure-activity relationship analysis of the splicing inhibitor herboxidiene. We identified features of the tetrahydropyran ring that mediate its interactions with SF3B and its ability to interfere with splicing. In the context of recent structures of SF3B bound to inhibitor, our results lead us to extend the model for early spliceosome assembly and inhibitor mechanism. We postulate that interactions between a carboxylic acid substituent of herboxidiene and positively charged SF3B1 side chains in the inhibitor binding channel are needed to maintain inhibitor occupancy while counteracting the SF3B transition to a dosed state that is required for stable U2 snRNP interactions with the intron.
引用
收藏
页码:520 / 528
页数:9
相关论文
共 50 条
  • [21] Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
    J William Harbour
    Elisha D O Roberson
    Hima Anbunathan
    Michael D Onken
    Lori A Worley
    Anne M Bowcock
    Nature Genetics, 2013, 45 : 133 - 135
  • [22] Aberrant splicing during erythroid differentiation in SF3B1 mutated sideroblastic anemia
    Conte, S.
    Vesterlund, L.
    Katayama, S.
    Karimi, M.
    Unneberg, P.
    Papaemmanuil, E.
    Jansson, M.
    Mortera-Blanco, T.
    Dimitriou, M.
    Sander, B.
    Skoog, T.
    Campbell, P.
    Kere, J.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2013, 37 : S24 - S25
  • [23] SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
    Visconte, V.
    Makishima, H.
    Jankowska, A.
    Szpurka, H.
    Traina, F.
    Jerez, A.
    O'Keefe, C.
    Rogers, H. J.
    Sekeres, M. A.
    Maciejewski, J. P.
    Tiu, R. V.
    LEUKEMIA, 2012, 26 (03) : 542 - 545
  • [24] Influence of SF3B1 gene mutation is different from that of Sf3B1 inhibitor in colorectal cancer
    Yamano, Tomoki
    Kubo, Shuji
    Matsubara, Nagahide
    Yano, Aya
    Tomita, Naohiro
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype
    Duetz, Carolien
    Westers, Theresia M.
    in 't Hout, Florentien E. M.
    Cremers, Eline M. P.
    Alhan, Canan
    Venniker-Punt, Bianca
    Visser-Wisselaar, Heleen A.
    Chitu, Dana A.
    de Graaf, Aniek O.
    Smit, Linda
    Jansen, Joop H.
    van de Loosdrecht, Arjan A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 798 - 803
  • [26] Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
    Valeria Visconte
    Ali Tabarroki
    Li Zhang
    Yvonne Parker
    Edy Hasrouni
    Reda Mahfouz
    Kyoichi Isono
    Haruhiko Koseki
    Mikkael A Sekeres
    Yogen Saunthararajah
    John Barnard
    Daniel Lindner
    Heesun J Rogers
    Ramon V Tiu
    Journal of Hematology & Oncology, 7
  • [27] Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts
    Visconte, Valeria
    Tabarroki, Ali
    Zhang, Li
    Parker, Yvonne
    Hasrouni, Edy
    Mahfouz, Reda
    Isono, Kyoichi
    Koseki, Haruhiko
    Sekeres, Mikkael A.
    Saunthararajah, Yogen
    Barnard, John
    Lindner, Daniel
    Rogers, Heesun J.
    Tiu, Ramon V.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [28] SF3B1/DNMT3A CO- MUTATION MIMICS FEATURES OF SOLE SF3B1 OR DNMT3A MUTATION DEPENDING ON STRESS CONDITIONS
    Wallace, LaShanale
    Cervantes, Ana Leal
    Metidji, Amina
    Myers, Jacquelyn
    Campbell, Koral
    Skorupa, Jordan
    Fields, Henry
    Rolle, Chandra
    Tillman, Heather
    Obeng, Esther
    EXPERIMENTAL HEMATOLOGY, 2022, 111 : S154 - S154
  • [29] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    LABORATORY INVESTIGATION, 2014, 94 : 50A - 50A
  • [30] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    MODERN PATHOLOGY, 2014, 27 : 50A - 50A